The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

LCMC Health officials announced the activation of their code grey plan at hospitals across the Greater New Orleans region.

A woman was injured when she fell out of a vehicle on the interstate. Your urine can tell you a lot about your health. A ...

Professor Tim Spector has issued an urgent warning to people who may wish to take Ozempic "without a medical need". Ozempic ...

A new report finds half of adults in the United States could be eligible for popular weight loss drugs. KYW medical editor Dr ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...